论文部分内容阅读
目的 探讨骨化三醇对老年女性骨质疏松症患者骨密度和血清骨代谢的影响.方法选择2015 年1 月~2017 年12 月在本院就诊的100 例老年女性骨质疏松症的患者作为观察对象, 随机分为对照组和实验组各50 例.实验组口服骨化三醇(每次0. 25 μg, 每日2 次) , 对照组口服单纯钙剂(醋酸钙胶囊, 每日1 粒), 两组疗程均为6 个月.评估、检测两组治疗前后骨密度和骨代谢指标, 比较两组的临床疗效.结果 实验组和对照组治疗后血清中的甲状旁腺激素( PTH)和骨钙素N端中分子片段( N-MID)水平较治疗前显著降低(P <0. 01), 25 羟基维生素 D3[25 (OH) D3] 和Ⅰ型前胶原 C 端前肽(PICP)水平较治疗前显著升高(P<0. 01), 且实验组的效果优于对照组, 两组之间各项指标比较差异均有统计学意义(P<0. 01).骨密度检测也发现补充骨化三醇能有效减缓老年女性的骨量丢失, 可以在6个月内提升骨密度( BMD) .结论 骨化三醇可以促进骨组织代谢, 有效地预防老年女性骨钙流失, 改善老年女性的骨质疏松症.“,”Objective To evaluate the effects of calcitriol on bone density and bone metabolism in older women with osteo-porosis. Methods 100 older women with osteoporosis were randomly divided into the experimental and control groups, 50 cases in each group. The experimental group received 0. 25 μg of calcitriol twice per day. The control group received one calcium acetate cap-sule once per day. Bone mineral density (BMD) and index of bone metabolism was measured at 3 and 6 months after treatment. Re-sults Compared with before treatment, at 6 months after treatment, the level of BMD increased significantly, the level of both para-thyroid hormone (PTH) and N-MID osteocalcin (N-MID) reduced significantly (P<0. 05), the level of 25 (OH) D3and C-terminal propeptide of procollagen type I (PICP) increased significantly (P<0. 05) in two groups. The therapeutic efficacy of calcit-riol was better than calcium acetate (P<0. 01). BMD measurement demonstrated that calcitriol effectively delayed bone loss. Con-clusion Calcitriol can promote bone metabolism, effectively prevent bone calcium loss and improve osteoporosis in older women.